Podcast: In conversation with… John Collinge

  • Post category:News / Research

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.

In Conversation with… John Collinge (link to podcast with listing options)